id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-311453-l6quzef6	Klopfenstein, Timothée	Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients	2020-08-13		.txt	text/plain	2675	154	55	CONCLUSION: Despite the small sample size in the group TCZ, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. We have recently published a retrospective study including 45 patients treated in our hospital, which shows that TCZ seems to reduce the number of COVID-19 severe cases and/or mortality (11) . Based on the medical literature, we checked several criteria before starting TCZ treatment: no contraindication to TCZ, confirmed COVID-19 with real-time reverse transcription (RT)-PCR SARS-CoV-2 RNA, failure of standard treatment, period since symptoms onset ≥ 5 days, oxygen therapy ≥ 4 liters/min, ≥ 25% of lung damages on chest computed tomography (CT) scan, and ≥ 2 parameters of inflammation or biological markers of mortality (with a high level) such as ferritin, CRP, D-dimer, lymphopenia, and/or lactate dehydrogenase.	./cache/cord-311453-l6quzef6.txt	./txt/cord-311453-l6quzef6.txt